{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:50:06Z","timestamp":1791615006101,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) remains a leading cause of morbidity and mortality, yet many promising drugs fail in late-stage development despite plausible biology and strong financial investment. This failure often reflects redundancy in the translational pathway rather than intrinsic lack of efficacy. Preclinical research continues to rely on narrow, reductionist models that poorly recapitulate the chronic, multifactorial nature of human CKD and its cardiovascular complications. Early-phase clinical trials frequently prioritise short-term surrogate endpoints and broad, heterogeneous CKD populations, diluting biologically coherent subgroups and obscuring clinically meaningful effects. Late-phase programmes, exemplified by the recent ocedurenone experience, are then terminated for neutral primary outcomes or safety concerns, with limited transparency and learning from negative data. We argue that CKD drug development must shift towards learning health systems built on human-relevant models, biology-driven enrichment, more appropriate and patient-centred endpoints, and adaptive trial platforms. Systematic reporting and shared analysis of failed and futile trials are essential to avoid repeating avoidable errors. Re-engineering this translational ecosystem is crucial to convert mechanistic insight into durable therapeutic advances for people living with CKD.<\/jats:p>","DOI":"10.1093\/joneph\/aajag157","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:42:44Z","timestamp":1780573364000},"page":"1108-1115","source":"Crossref","is-referenced-by-count":0,"title":["Drugs lost in translation in CKD: from redundant designs to learning systems"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1996","authenticated-orcid":false,"given":"Carmine","family":"Zoccali","sequence":"first","affiliation":[{"name":"Institute of Molecular Biology and Genetics (Biogem) , Ariano Irpino ,","place":["Italy"]},{"name":"Renal Research Institute , New York, NY ,","place":["United States"]},{"name":"Associazione Ipertensione Nefrologia Trapianto Renale (IPNET) , Reggio Calabria ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"Associazione Ipertensione Nefrologia Trapianto Renale (IPNET) , Reggio Calabria ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-0616","authenticated-orcid":false,"given":"Giovanni","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health, The University of Sydney , Sydney ,","place":["Australia"]},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-261X","authenticated-orcid":false,"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, (Past Director), ASST Lecco , Lecco ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026101002224463800_aajag157-B1","author":"National Kidney Foundation"},{"key":"2026101002224463800_aajag157-B2","author":"Docwire News"},{"key":"2026101002224463800_aajag157-B3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med."},{"key":"2026101002224463800_aajag157-B4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"2026101002224463800_aajag157-B5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"2026101002224463800_aajag157-B6","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1093\/NDT\/GFM893","article-title":"Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria","volume":"23","author":"Heerspink","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"2026101002224463800_aajag157-B7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/J.AJKD.2009.05.011","article-title":"Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial","volume":"54","author":"Akizawa","year":"2009","journal-title":"Am J Kidney Dis."},{"key":"2026101002224463800_aajag157-B8","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMOA1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med."},{"key":"2026101002224463800_aajag157-B9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med."},{"key":"2026101002224463800_aajag157-B10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jacbts.2025.04.003","article-title":"Derisking phase II clinical trials in heart failure: a position paper from JACC: basic to translational science and the heart failure collaboratory","volume":"10","author":"Mann","year":"2025","journal-title":"JACC Basic Transl Sci."},{"key":"2026101002224463800_aajag157-B11","doi-asserted-by":"publisher","author":"Baldi","DOI":"10.1136\/BMJOPEN-2016-013482"},{"key":"2026101002224463800_aajag157-B12","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2023.24977","article-title":"Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors","volume":"6","author":"Jentzsch","year":"2023","journal-title":"JAMA Netw Open."},{"key":"2026101002224463800_aajag157-B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/S12325-021-01927-Z","article-title":"A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives","volume":"39","author":"Evans","year":"2022","journal-title":"Adv Ther."},{"key":"2026101002224463800_aajag157-B14","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/CVR\/CVAD083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res."},{"key":"2026101002224463800_aajag157-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000421087","volume-title":"Experimental and Genetic Rat Models of Chronic Renal Failure","author":"Gretz","year":"1993"},{"key":"2026101002224463800_aajag157-B16","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.86230","article-title":"Effect of blood pressure control on cardiovascular events in patients with chronic kidney disease: a systematic review","volume":"17","author":"Ahmed","year":"2025","journal-title":"Cureus"},{"key":"2026101002224463800_aajag157-B17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4212\/CJHP.V70I6.1706","article-title":"The importance of negative and neutral studies for advancing clinical practice","volume":"70","author":"Bresee","year":"2017","journal-title":"Can J Hosp Pharm."},{"key":"2026101002224463800_aajag157-B18","doi-asserted-by":"publisher","author":"Haribabu","DOI":"10.4108\/EAI.13-11-2024.2355682"},{"key":"2026101002224463800_aajag157-B19","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/J.CELL.2023.07.036","article-title":"TGF-\u03b2 signaling in health and disease","volume":"186","author":"Massagu\u00e9","year":"2023","journal-title":"Cell"},{"key":"2026101002224463800_aajag157-B20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/JOIM.70015","article-title":"Inter-organ crosstalk: the kidney's role in systemic health and disease","volume":"298","author":"Zoccali","year":"2025","journal-title":"J Intern Med."},{"key":"2026101002224463800_aajag157-B21","doi-asserted-by":"publisher","DOI":"10.1177\/20543581231213798","article-title":"Association between arterial stiffness and measures of autonomic dysfunction in people with chronic kidney disease","volume":"10","author":"Davies","year":"2023","journal-title":"Can J Kidney Health Dis."},{"key":"2026101002224463800_aajag157-B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMRA1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med."},{"key":"2026101002224463800_aajag157-B23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.116.023538","article-title":"Development and evolution of a hierarchical clinical composite end point for the evaluation of drugs and devices for acute and chronic heart failure: a 20-year perspective","volume":"134","author":"Packer","year":"2016","journal-title":"Circulation"},{"key":"2026101002224463800_aajag157-B24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/PDS.3485","article-title":"Evidence of subgroup-specific treatment effect in the absence of an overall effect: is there really a contradiction?","volume":"22","author":"Abrahamowicz","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2026101002224463800_aajag157-B25","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCT.2022.106740","article-title":"Inclusion and diversity in clinical trials: actionable steps to drive lasting change","volume":"116","author":"Kelsey","year":"2022","journal-title":"Contemp Clin Trials."},{"key":"2026101002224463800_aajag157-B26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/CLPT.2010.233","article-title":"Enrichment of clinical study populations","volume":"88","author":"Temple","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"2026101002224463800_aajag157-B27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/S13318-023-00837-5","article-title":"Pharmacokinetics and drug\u2013drug interaction of ocedurenone (KBP-5074) in vitro and in vivo","volume":"48","author":"Wang","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"2026101002224463800_aajag157-B28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/S12916-023-03113-0","article-title":"A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies","volume":"21","author":"Modi","year":"2023","journal-title":"BMC Med."},{"key":"2026101002224463800_aajag157-B29","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1017\/CTS.2023.537","article-title":"Recent innovations in adaptive trial designs: a review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J Clin Transl Sci."},{"key":"2026101002224463800_aajag157-B30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/BMJEBM-2020-111573","article-title":"Patient-reported outcome measures (PROMs) as proof of treatment efficacy","volume":"27","author":"Kluzek","year":"2022","journal-title":"BMJ Evid Based Med."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1108\/70679173\/aajag157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1108\/70679173\/aajag157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:22:50Z","timestamp":1791613370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/6\/1108\/8763266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag157","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]}}}